Table 1.

Patient*	Age (yrs)†	Histology	Stage‡/grade	Chemotherapy Treatment	Specimen Type	Patient Status§
A	60	Serous/high grade OVCA	IIIC/3	Post surgery: 8 cycles taxane/carboplatin and etoposide	Ascites at surgery, frozen	DOD, 19 months
B	65	Serous/papillary OVCA	NIC/3	Pre specimen collection: 3 cycles taxane/cisplatin, recurrence. Post specimen: 4 cycles taxane/cisplatin	Ascites from paracentesis, frozen	DOD, 11 months
C	65	Serous/high grade OVCA	IIIC/3	Neoadjuvant pre specimen: 3 cycles taxane/carboplatin. Post surgery: 6 cycles paclitaxel/carboplatin IP	Ascites at surgery, frozen	DOD, 10 months
D	51	Serous/papillary OVCA	IIIC/3	Post surgery: 6 cycles taxane/cisplatin	Ascites at surgery, frozen	DOD, 13 months
E	54	Serous/high grade OVCA	IIIC/3	Post surgery: 6 cycles taxane IV, cisplatin IP	Ascites at surgery, frozen	AWD, 11 months
F	74	Serous/papillary OVCA	IIIC/3	Post surgery: 6 cycles taxane/cisplatin	Ascites at surgery, frozen	AWD, 11 months
G	69	Clear cell OVCA	IIIC/3	None	Ascites at surgery, fresh	DOD, 2 months
H	86	Carcinosarcoma [Malignant Mixed Mesodermal]	IIB/3	None	Ascites at surgery, fresh	AWD, 6 months
I	46	Serous/high grade OVCA	IIIC/3	Post surgery: 8 cycles taxane/carboplatin	Metastasis to omentum, fresh	NED, 10 months

^*All patients were chemo naive at the time of surgery, except Patients B and C, who received standard taxane/platinum combination chemotherapy.

^†At the time of diagnosis.

^‡International Federation of Obstetrics and Gynecology (FIGO) System.

^§Post-Diagnosis; DOD = died of disease; AWD = alive with disease; NED = alive with no evidence of disease.